OCL 500 Treatment of Women With Symptomatic Uterine Fibroids

Inclusion Criteria: * Premenopausal women with symptomatic uterine fibroids * Willing and able to provide informed consent * Fibroids visible by ultrasound or non-contrast magnetic resonance imaging * Fibroids with a minimum diameter of 4cm for a single fibroid or 3cm where there are 2 or more fibroids; minimum total fibroid burden 33cc * Documented ovulation by Luteinizing Hormone (LH) testing * Follicle Stimulating Hormone (FSH) value \>40 IU/L within 3 months prior to procedure * Pelvic examination within 6 months prior to procedure * Normal Pap smear Exclusion Criteria: * Positive pregnancy test * Uterine size \> 20 weeks gestation * Fibroids that are more than 50% submucosal * Individual fibroids \> 12cm in diameter, or total fibroid burden \> 905cc * Pedunculated subserosal fibroids with an attachment to the uterus less than 50% of the greatest diameter of the fibroid * Fibroids situated in the cervix * Abnormally large ovarian arteries * Uterine pathology other than fibroids * History of gynecologic malignancy * Active pelvic infection or history of pelvic inflammatory disease * Undiagnosed pelvic mass outside the uterus * History of chemotherapy or radiation to the abdomen or pelvis * Intra-Uterine Device (IUD) in position * History of, or ongoing, hemolytic anemia * Severe cerebrovascular disease defined by a cerebrovascular accident within 6 months of treatment * Anticoagulant therapy or known bleeding disorder * Treatment with Gonadotropin Releasing Hormone (GnRH) agonists within the previous 6 weeks * Received another investigational agent within past 12 weeks * Compromised hematopoietic function * Compromised hepatic function * Compromised renal function * BMI \> 38 * Claustrophobia * Contraindication to angiography * Contraindication to magnetic resonance imaging (MRI) or MRI contrast agents * Allergy to contrast agents * Allergy to bovine collagen * Patient desires to become pregnant, or does not agree to contraception during study